首页> 美国卫生研究院文献>Diabetes Therapy >Achieving a Preoperative Target HbA1c of  69 mmol/mol in Elective Vascular and Orthopedic Surgery: A Retrospective Single Center Observational Study
【2h】

Achieving a Preoperative Target HbA1c of  69 mmol/mol in Elective Vascular and Orthopedic Surgery: A Retrospective Single Center Observational Study

机译:在选择性血管和骨科手术中实现69 mmol / mol的术前目标HbA1c:回顾性单中心观察性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionDiabetes mellitus (DM) is present in 10–15% of the surgical population. It is a known risk factor for adverse postoperative outcomes. UK perioperative guidance recommends optimizing glycemic control preoperatively, aiming for a target glycated hemoglobin (HbA1c) of < 69 mmol/mol. However, real-world compliance with this guidance remains unknown. The aim of our study was to determine how many patients with DM undergoing elective orthopedic and vascular surgery had a preoperative HbA1c of < 69 mmol/mol. We also reviewed the surgical reasons for non-concordance with the recommended preoperative HbA1c target.
机译:简介糖尿病(DM)出现在10-15%的外科手术人群中。这是术后不良后果的已知危险因素。英国围手术期指南建议在术前优化血糖控制,以使目标糖化血红蛋白(HbA1c)达到<69 mmol / mol。但是,在现实世界中是否遵守该指南仍然未知。我们研究的目的是确定接受选择性骨科和血管外科手术治疗的DM患者术前HbA1c≤69 mmol / mol。我们还回顾了与推荐的术前HbA1c靶标不一致的手术原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号